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 New evidence is mounting that cancer cells can evolve to become infectious agents and 
be transmitted between individuals.  
 
The current view of carcinogenesis is that normal cells are transformed into 
tumour cells by mutations that activate oncogenes, silence tumour suppressor genes or 
trigger genetic instabilities. As a consequence, every tumour is the result of a unique 
evolutionary process that begins in its individual host and ends with the elimination of the 
tumour or the death of the host. Two recent studies, however, suggest that tumour cells 
can behave like infectious agents and move from one host to another 
1,2.  
It has long been suspected that canine transmissible venereal tumour (CTVT) is 
transferred between dogs by implantation of tumour cells from donor to the recipient, 
where the tumour grows as an allograft 
3. Several lines of evidence provided indirect 
support for this hypothesis. The tumour can only be induced by the implantation of whole 
tumour cells but not by cell extracts or dead cells.  Normal canine cells have 78 
chromosomes but karyotypes of tumour cells isolated from different animals have shown 
a characteristic and persistent pattern of aneuploidy with 58 to 59 chromosomes 
4. In 
addition, a LINE-1 insertion close to c-myc has been found in all tumour samples 
5. If the 
allograft transfer hypothesis is correct, tumour cells from different animals should be 
genetically clustered and different from normal cells of the host animal. Formal proof of the allograft hypothesis for CTVT was recently provided by Claudio Murgia, Robin 
Weiss and colleagues 
1.  
They studied tumour and normal cells isolated from dogs harboring CTVT from 
three continents. Using a combination of dog leukocyte antigen (DLA) haplotyping, 
microsatellite DNA and mitochondrial DNA sequencing, they proved that all the tumours 
are closely related genetically and different from normal cells of the host dog 
1.  
Sequencing of microsatellite DNA regions showed that tumours from different 
animals had less variability than what is observed within the most inbred breed of dogs. 
Therefore, the tumours could not arise from the separate transformations of cells within 
individual animals but were transmitted from one dog to another confirming the spread of 
this tumour from an ancestral clone. Moreover, by comparing tumour and various canine 
microsatellite markers, it was estimated that the clone had arisen between 250 and 2500 
years ago making it the oldest known continuously replicating somatic cell line 
1.  
In an independent study, Pearse and Swift 
2 have reported that devil facial tumour 
disease is caused by horizontal tumour cell transmission between Tasmanian devils. 
Cancer cells isolated from different animals that harbored tumours of different age and 
size share the same aneuploid karyotype. Furthermore, one animal had a constitutional 
pericentric inversion of chromosome 5 but this abnormality was not found in any of the 
cells isolated from the tumour, providing further support that the tumour did not arise 
from host cells. 
Given that tumour cells can behave like infectious agents in some mammals, the 
question arises if infectious transmission of cancer can also occur in humans. There is no 
evidence (yet) for direct horizontal transmission of tumour cells between humans with normal social contact. The only known physiological route for tumour cell transmission 
in humans is during pregnancy. Every year about 3,500 pregnant women in the United 
States have a concomitant malignancy. Transplacental transmission of lymphoma, acute 
leukaemia, melanoma and carcinoma from mother to fetus have been observed 
6. Acute 
leukaemia cells have also been transferred between fetuses (in mothers with a multiple 
pregnancy) followed by the development of disease in both fetuses 
6.  
Organ transplantation represents another possible route of tumour cell 
transmission between humans. The immunosuppressive therapy required for survival of 
the transplanted organ blunts immune surveillance and may facilitate engraftment and 
growth of donor derived tumour cells. Fortunately, the development of donor derived 
tumours in solid organ transplant recipients is rare (0.04%) 
7. The main culprit seems to 
be malignant melanoma that is undetected in the donor at the time of organ harvest: in 
one report, metastatic melanoma developed in both kidney and liver recipients from a 
donor with occult disease 
8. Another example is the transfer of haematological 
malignancy by haematopoietic stem cell transplantation 
9. Again the frequency is low 
(0.06%). Finally, we came across one case report where a surgeon developed malignant 
fibrous histiocytoma after accidentally injuring his palm during surgical removal of the 
tumour from a patient 
10. 
The transfer of tumour cells between individuals seems to be a rare event in 
humans. Differences in the human lymphocyte antigens may protect against successful 
tumour cell engraftment by inducing an immune response that eliminates the implanted 
cells. CTVT cells avoid immune mediated destruction by down-regulating DLA 
expression 
1. This is an important adaptation since complete absence of DLA antigens would allow natural killer cells to destroy the tumour, while normal expression of DLA 
antigens activates cytotoxic T-cells with a similar outcome. In many dogs, an immune 
attack against CTVT ultimately develops and leads to tumour eradication and immunity 
to re-challenge 
3. This evidence also strengthens the hope that the immune system can be 
coached to eradicate established tumours in humans. 
The emergence of multi-cellular life forms required cooperation between cells of 
a given organism. Cancer entails loss of this cooperation, and from the perspective of 
evolutionary game theory cancer is a ‘defector’ 
11. Breakdown of cooperation can lead to 
the death of the host, but then the tumour also meets its own demise. Therefore, a tumour, 
which can be transmitted from one host to the next, maneuvers around the specific 
evolutionary mechanism that is meant to control it.  
Why is cancer in general not transmissible between people? A main reason is 
tissue graft rejection caused by MHC incompatibility. The cancer cells of the donor 
should induce a vigorous immune response in a healthy recipient. Tumour transfer in 
mice is only possible between syngeneic animals (that share the same MHC) or if the 
recipient is severely immunosuppressed. This leads to the interesting speculation, 
suggested by Murgia et al
1,  that a main reason for MHC diversity in humans and other 
vertebrates is to ensure that cancer is not an infectious disease.  
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